Clinical trial
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma: A Randomized, Controlled, Open-label, Single-center Phase II Clinical Trial
NCT05503667 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma: A Randomized, Controlled, Open-label, Single-center Phase II Clinical Trial
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 1, 2022
- Completion date
- December 31, 2028
- Enrollment
- 96 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
egfr gene mutation, lung adenocarcinoma stage iii, lung adenocarcinoma stage iv